22,263
edits
Changes
Jump to navigation
Jump to search
m
{{Construction Site}} HP802-247 is an experimental spray treatment for venous leg ulcers. The potential value of this spray is that it could treat those people whose skin will not heal with conventional treatment (such as compression bandages and dressings), and for whom the only alternative option could be skin graft.<ref>{{cite webREFweb | last= | first= | date=2012-08-03 | title=Spray-on-skin' treatment for leg ulcers | url = http://www.nhs.uk/news/2012/08august/pages/spray-on-skin-treatment-for-leg-ulcers.aspx | title publisher= 'Spray-on-skin' treatment for leg ulcers NHS | accessdate = 2012-11-24 | date = 2012-08-03 | publisher = NHS}}</ref>
==References==<div class='references-small'><references/></div>{{REF}}
[[Category:Construction Site]]
no edit summary
== HP802-247 ==
The new spray (HP802-247) consisted of a combination of donated skin cells and proteins.
The study was conducted by researchers from the University of Miami and other institutions in the US and was funded by Healthpoint Biotherapeutics, a biotech company that specialises in wound care products. The study was published in the peer-reviewed medical journal The Lancet.<ref>{{cite webREFweb | last= | url first= | date= http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)60644-8/abstract201209 | title = Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial | accessdate url= 2012http://www.thelancet.com/journals/lancet/article/PIIS0140-116736(12)60644-248/abstract | date publisher= 201209The Lancet | publisher accessdate= The Lancet2012-11-24}}</ref>
The new treatment is a form of cell treatment applied as a spray. It contains keratinocytes, which are the main cell type in the outer layer of the skin, and fibroblasts, a cell type found in connective tissue. These cells had been grown in the laboratory and were originally derived from newborn foreskin samples (removed during circumcision). This was a phase 2 trial that aimed to see whether the new treatment was effective and safe, and to find out the best dose to use. If the results of phase 2 trials are positive (as these trial results were) they will usually be followed by larger phase 3 trials.
[[Category:Foreskin Products]]
[[Category:CircLeaks]]
[[Category:From IntactWiki]]